title: KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.
abstract: OBJECTIVE
  A recent report demonstrated that KLF6 IVS1 -27G>A substitution increases the transcription of alternatively spliced isoforms; this action was suggested to be associated with prostate cancer (pCA). To evaluate these findings among the Finnish population, a total of 3348 samples were analysed.
  
  
  METHODS
  The variant was genotyped in 164 patients with familial pCA, 852 patients with unselected pCA, 459 patients with benign prostate hyperplasia (BPH), 923 male population controls, and 950 men from a Finnish prostate-specific antigen (PSA) screening trial with PSA levels less than 1.0ng/ml. Odds ratios (ORs) and corresponding 95% confidence intervals (95%CIs) were calculated by using logistic regression to estimate pCA risk.
  
  
  RESULTS
  Association testing revealed no significant differences between familial prostate cancer patients and population controls (OR: 0.84; 95%CI, 0.56-1.28; p=0.42), unselected cases and controls (OR: 0.95; 95%CI, 0.76-1.19; p=0.63), or BPH cases and controls (OR: 1.12; 95%CI, 0.86-1.46; p=0.39). pCA and BPH cases were also compared with PSA-screened controls. None of these analyses revealed any significant associations.
  
  
  CONCLUSIONS
  Our results do not support the suggested association of KLF6 IVS1 -27G>A germline polymorphism with pCA risk and also suggest that the variant is not a risk allele for BPH in the Finnish population.
authors.affiliation: Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, University of Tampere, Finland.
authors.forename: Eija H
authors.initials: EH
authors.lastname: Seppälä
authors.forename: Ville
authors.initials: V
authors.lastname: Autio
authors.forename: Priya
authors.initials: P
authors.lastname: Duggal
authors.forename: Tarja
authors.initials: T
authors.lastname: Ikonen
authors.forename: Ulf-Håkan
authors.initials: UH
authors.lastname: Stenman
authors.forename: Anssi
authors.initials: A
authors.lastname: Auvinen
authors.forename: Joan E
authors.initials: JE
authors.lastname: Bailey-Wilson
authors.forename: Teuvo L J
authors.initials: TL
authors.lastname: Tammela
authors.forename: Johanna
authors.initials: J
authors.lastname: Schleutker
mesh_terms: D000225:Adenine; D005387:Finland / Q000453:epidemiology; D014644:Genetic Variation; D005838:Genotype; D018095:Germ-Line Mutation; D006147:Guanine; D006801:Humans; D000075723:Kruppel-Like Factor 6; D051741:Kruppel-Like Transcription Factors / Q000097:blood / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011470:Prostatic Hyperplasia / Q000453:epidemiology / Q000235:genetics; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000097:blood / Q000235:genetics*; D012307:Risk Factors; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: C105465:KLF6 protein, human; D000075723:Kruppel-Like Factor 6; D051741:Kruppel-Like Transcription Factors; D011518:Proto-Oncogene Proteins; D025521:Tumor Suppressor Proteins; D006147:Guanine; D000225:Adenine